SG10201703378UA - Anticancer agent free of adverse reactions - Google Patents
Anticancer agent free of adverse reactionsInfo
- Publication number
- SG10201703378UA SG10201703378UA SG10201703378UA SG10201703378UA SG10201703378UA SG 10201703378U A SG10201703378U A SG 10201703378UA SG 10201703378U A SG10201703378U A SG 10201703378UA SG 10201703378U A SG10201703378U A SG 10201703378UA SG 10201703378U A SG10201703378U A SG 10201703378UA
- Authority
- SG
- Singapore
- Prior art keywords
- anticancer agent
- adverse reactions
- agent free
- free
- adverse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dermatology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013209574 | 2013-10-04 | ||
| JP2013237219A JP5721806B2 (en) | 2013-10-04 | 2013-11-15 | Anticancer drugs without side effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201703378UA true SG10201703378UA (en) | 2017-05-30 |
Family
ID=52778484
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506026PA SG11201506026PA (en) | 2013-10-04 | 2014-02-07 | Anticancer agent free of adverse reactions |
| SG10201703378UA SG10201703378UA (en) | 2013-10-04 | 2014-02-07 | Anticancer agent free of adverse reactions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506026PA SG11201506026PA (en) | 2013-10-04 | 2014-02-07 | Anticancer agent free of adverse reactions |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP5721806B2 (en) |
| KR (1) | KR101678881B1 (en) |
| CN (1) | CN104981245B (en) |
| HK (1) | HK1214145A1 (en) |
| SG (2) | SG11201506026PA (en) |
| TW (1) | TW201513863A (en) |
| WO (1) | WO2015049883A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10111955B2 (en) | 2014-12-04 | 2018-10-30 | Delta-Fly Pharma, Inc. | PEG derivative |
| PL3928835T3 (en) * | 2020-05-14 | 2024-02-12 | Delta-Fly Pharma, Inc. | Water-soluble polymeric derivative of venetoclax |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4694776B2 (en) | 2003-07-29 | 2011-06-08 | 株式会社ヤクルト本社 | Fine particle composition or liposome preparation |
| PT1675622T (en) | 2003-09-17 | 2017-09-19 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| CN102395370A (en) * | 2009-04-17 | 2012-03-28 | 安龙制药公司 | Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| BR112012001395A2 (en) | 2009-07-22 | 2019-09-24 | Enzon Pharmaceuticals Inc | Method for treating her2-positive cancer in a mammal Method for increasing her2-receptor antagonist herds in a mammal by presenting a her2-positive cancer Method for inhibiting the growth or proliferation of her2-positive cells in a mammal |
| JP5901073B2 (en) * | 2009-11-18 | 2016-04-06 | ネクター セラピューティクス | Salt forms of multi-arm polymer-drug conjugates |
| CN103755949B (en) * | 2009-12-25 | 2016-04-13 | 天津键凯科技有限公司 | Multi-arm polyethylene glycol derivative and with the binding substances of medicine and gel |
| US8754190B2 (en) * | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
-
2013
- 2013-11-15 JP JP2013237219A patent/JP5721806B2/en not_active Expired - Fee Related
- 2013-12-02 TW TW102144080A patent/TW201513863A/en unknown
-
2014
- 2014-02-07 CN CN201480006400.1A patent/CN104981245B/en not_active Expired - Fee Related
- 2014-02-07 KR KR1020157021404A patent/KR101678881B1/en active IP Right Grant
- 2014-02-07 SG SG11201506026PA patent/SG11201506026PA/en unknown
- 2014-02-07 SG SG10201703378UA patent/SG10201703378UA/en unknown
- 2014-02-07 WO PCT/JP2014/052877 patent/WO2015049883A1/en active Application Filing
-
2016
- 2016-02-24 HK HK16102091.6A patent/HK1214145A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1214145A1 (en) | 2016-07-22 |
| WO2015049883A1 (en) | 2015-04-09 |
| JP2015091765A (en) | 2015-05-14 |
| JP5721806B2 (en) | 2015-05-20 |
| CN104981245B (en) | 2017-10-03 |
| CN104981245A (en) | 2015-10-14 |
| KR20150103749A (en) | 2015-09-11 |
| KR101678881B1 (en) | 2016-11-23 |
| SG11201506026PA (en) | 2015-09-29 |
| TW201513863A (en) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201421334D0 (en) | Synthesis of aeizeolite | |
| IL239203A0 (en) | Semifluorocarbon compound containing contrast agent | |
| EP3919505C0 (en) | Uses of cas9-nucleic acid complexes | |
| SG11201505827TA (en) | Reactor | |
| IL243323A0 (en) | Anticancer combinations | |
| GB2517174B (en) | Assessment of structural health | |
| HK1203811A1 (en) | Anticancer agent | |
| EP2971029A4 (en) | Preparation of malto-oligosaccharides | |
| GB2515870B (en) | Reactor | |
| GB201320417D0 (en) | Mixing reactors | |
| SG11201507648RA (en) | Liquid quick-setting agent | |
| GB201406931D0 (en) | Reactor | |
| GB2514842B (en) | Agitator assembly | |
| IL245157A0 (en) | Antitumor agent | |
| EP2837387A4 (en) | Anticancer agent | |
| EP2970642A4 (en) | Refresh agent | |
| HK1204916A1 (en) | Pharmaceutical application of anhydroicaritin | |
| HK1214145A1 (en) | Anticancer agent free of adverse reactions | |
| EP2812807A4 (en) | True-ownership of shared data | |
| GB201603522D0 (en) | Pyrazolochalcones as potential anticancer agents | |
| EP3037100A4 (en) | Muscle-atrophy-preventing agent | |
| GB201320732D0 (en) | Methods of chemical synthesis | |
| TWM476074U (en) | Motherboard of vehicle | |
| IL224699A0 (en) | Shielding of structures | |
| ZA201405720B (en) | Diagnosis of malaria |